XinYue Biologics Completes Series A+ Strategic Financing, Partners with XtalPi to Forge a New Paradigm in Drug Discovery

VCBeat learned第一时间获悉，近日，NewDEL BiotechAnnounced the completion by a global leading AI + automation technology platform companyXtalPi(XTALPI-P, 2228.HK) led the A+ round strategic investment. NewDEL Biotech's DNA Encoded Library (DEL) technology will deeply collaborate with XtalPi’s AI platform technology to accelerate the development and commercialization of innovative drug pipelines. This round of financing will expedite the in-depth development of NewDEL Biotech’s DEL+AI technology platform and the layout of innovative pipelines, further enhancing the efficiency and success rate in early-stage drug discovery.

NewDEL Biotech has deep technical accumulation and rich practical experience in DNA-encoded library (DEL) technology. Its DEL technology can rapidly generate a vast number of compound molecules and achieve efficient screening through a unique encoding method. XtalPi is a pioneer and leading company in the field of AI-driven drug discovery. Its AI drug discovery platform integrates high-precision quantum physics, computational chemistry algorithms, and over hundreds of AI models, enabling efficient exploration of ultra-large-scale drug chemical space. It designs and optimizes molecular structures that are both innovative and suitable for drug development, accelerating the clinical translation of innovative pipelines.

The two parties will deeply collaborate in target discovery, molecular optimization, and preclinical development to accelerate the new drug R&D process. This powerful collaboration model is expected to break the efficiency bottleneck of traditional drug R&D and provide stronger technical support for the discovery of innovative drugs.

Currently, drug development faces numerous challenges such as long cycles, high costs, and low success rates. The introduction of AI technology brings new hope for solving these problems. DEL technology can rapidly generate hundreds of millions of compound molecules, providing a rich foundation of wet-lab experimental data for AI models. Meanwhile, AI technology can quickly identify potential drug targets and optimize compound structures through machine learning and big data analysis, significantly shortening the drug development cycle.

This collaboration deeply integrates DEL technology with AI technology, which is expected to achieve more efficient target discovery and compound screening in the early stages of drug development. Through in-depth analysis of DEL screening results using AI algorithms, the structure and performance of compounds can be further optimized, enhancing the drug-likeness of molecules. This technological fusion not only accelerates the innovation process of drug development but also reduces R&D costs while increasing success rates.

With the rapid development of biotechnology and information technology, the integration of AI and biopharmaceuticals has become an important trend in the industry. The collaboration between NewDEL Biotech and XtalPi is a response to this trend. In the future, with continuous technological advancements and the expansion of application scenarios, the fusion of DEL technology and AI will bring more possibilities to drug discovery.

XtalPi ("XtalPi Holdings Limited", Stock Abbreviation: XtalPi-P, XTALPI-P, Stock Code: 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology. It is an innovative R&D platform based on quantum physics, empowered by artificial intelligence, and driven by robotics.

The company combines first-principles calculations based on quantum physics, artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and materials science R&D solutions and services for global and domestic companies in industries such as pharmaceuticals and materials science (including agrotechnology, energy, new chemicals, and cosmetics).

Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech" for short) is a clinical-stage innovative drug research and development company incubated and controlled by the Guangdong Small Molecule Innovative Drug Innovation Center. Established in April 2021, the company focuses on DNA-encoded compound library (DEL) technology as its core, building multiple 0-1 drug discovery technology platforms (DEL+X), and possesses a compound library with over 100 billion physical molecules. Its unique DEL live-cell screening technology can effectively screen difficult-to-express and purify targets, significantly expanding the range of targets and hit rates for new drug screening. With the mission of "empowering new drug development through distinctive technologies and making affordable quality medicines for the people," NewDEL Biotech aims to become an internationally leading biopharmaceutical company with a strong focus on innovative drug research and development.